Evaluation of chloroquine blood levels.

Phase 1

• Conditions: Vivax Malaria, Coronavirus innfections; C01.610.752.530.700; C01.925.782.600.550.200

• Registration Number: RBR-6mjqrf
• Lead Sponsor: Fundação Oswaldo Cruz

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-05-27
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Data analysis completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Men,
Non-pregnant and non-breastfeeding women
Within the age range 18 to 50 years old
Body Mass index range 19 to 28,5 Kg/m2
Health volunteers
Signed Informed Consent

Exclusion Criteria

hypersensitivity to the drug (clhoroquine): Previous pathologies that could influence the absorption distribution or excretion of the drug; Positive G6PD deficiency quantitative or pregnancy test. Use o concomitant medicines; Any clinical or laboratory exam abnormality;
Smokers; heavy coffee drinkers (>5 cups/Day); Abusive alcohol use: use of any treatment within 2 weeks before the study;Any previous hospitalization with 8 weeks before the study: Any previous treatment with known drug interaction with the test drug within 03 months; Blood donation greater than 450ml 03 months prior the study, or 1500ml in the previous 12 months; Use of Cyp 450 Inductors medications 4 weeks prior; Consume of alcohol or grapefruit 48h prior hospitalization;

Study & Design

• Study Type: Intervention
• Study Design: Not specified